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BACKGROUND: Patients with heart failure (HF) and reduced ejection 
fraction will experience multiple hospitalizations for heart failure during 
the course of their disease. We assessed the efficacy of dapagliflozin on 
reducing the rate of total (ie, first and repeat) hospitalizations for heart 
failure in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-
Outcomes in Heart Failure).
METHODS: The total number of HF hospitalizations and cardiovascular 
deaths was examined by using the proportional-rates approach of 
Lei-Wei-Yang-Ying and a joint frailty model for each of recurrent HF 
hospitalizations and time to cardiovascular death. Variables associated 
with the risk of recurrent hospitalizations were explored in a multivariable 
Lei-Wei-Yang-Ying model.
RESULTS: Of 2371 participants randomly assigned to placebo, 
318 experienced 469 hospitalizations for HF; of 2373 assigned 
to dapagliflozin, 230 patients experienced 340 admissions. In a 
multivariable model, factors associated with a higher risk of recurrent 
HF hospitalizations included higher heart rate, higher N-terminal pro-B-
type natriuretic peptide, and New York Heart Association class. In the 
Lei-Wei-Yang-Ying model, the rate ratio for the effect of dapagliflozin 
on recurrent HF hospitalizations or cardiovascular death was 0.75 (95% 
CI, 0.65–0.88), P=0.0002. In the joint frailty model, the rate ratio for 
total HF hospitalizations was 0.71 (95% CI, 0.61–0.82), P<0.0001, 
whereas, for cardiovascular death, the hazard ratio was 0.81 (95% CI, 
0.67–0.98), P=0.0282.
CONCLUSIONS: Dapagliflozin reduced the risk of total (first and repeat) 
HF hospitalizations and cardiovascular death. Time-to-first event analysis 
underestimated the benefit of dapagliflozin in HF and reduced ejection 
fraction.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: 
NCT03036124.
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Although it is recognized that the natural histo-ry of heart failure is characterized by repeated hospitalizations and that their impact at a per-
sonal, health care system, and societal level are also 
well understood, these recurrent events are usually 
not accounted for when evaluating the effect of treat-
ment. Even recent clinical trials underpinning treatment 
recommendations in guidelines examined the efficacy 
of therapy according to time-to-first event analysis, 
based on a single event per participant, ignoring fur-
ther events after a first hospitalization.1–3 Given the sig-
nificance of repeat hospitalizations, it is important to 
examine whether a new treatment for heart failure re-
duces not only first, but also total admissions. It is com-
mon to evaluate the effect of therapy on repeat events 
(relapses or recurrences) in other areas of medicine, 
including neurology (eg, epilepsy, migraine, multiple 
sclerosis), pulmonology (eg, asthma, chronic obstruc-
tive pulmonary disease), gerontology (eg, falls), and 
psychiatry (eg, schizophrenia). This approach has also 
been used in coronary artery disease of late,4–7 but has 
not routinely been applied in heart failure. In part, this 
relates to the uncertainty about which statistical meth-
ods are most appropriate when death, as well as the 
repeating nonfatal event, is common.8,9 Such methods 
need to account for not only the correlation of non-
fatal events with each other, but also the association 
between nonfatal events and death (which precludes 
further hospitalization), especially if the treatment un-
der investigation reduces death. Recently, joint frailty 
models that account for within-subject event depen-
dence and provide separate estimates for rate ratios for 
repeat events (hospitalizations) and the hazard ratio for 
the terminal event (death) have emerged as an attrac-
tive option.9
In the DAPA-HF trial (Dapagliflozin and Prevention 
of Adverse-Outcomes in Heart Failure), the sodium-
glucose cotransporter 2 inhibitor, dapagliflozin, was 
shown to reduce the risk of cardiovascular death and 
a first episode of worsening heart failure (HF) in pa-
tients with heart failure and reduced ejection fraction 
(HFrEF).3 In this analysis of DAPA-HF, we describe the 
efficacy of dapagliflozin on the predefined secondary 
end point of total failure hospitalizations (first and re-
current) and cardiovascular death by using a joint frailty 
model.
METHODS
In DAPA-HF, patients with HFrEF, with and without type 2 
diabetes, were randomly assigned in a double-blind, placebo-
controlled, event-driven trial.3,10,11 Dapagliflozin, a sodium-glu-
cose cotransporter 2 inhibitor, at a dose of 10 mg once daily, in 
addition to standard care, was compared with matching pla-
cebo. The design, baseline characteristics, and primary results 
have been published previously.3,10,11 The Ethics Committee of 
the 410 participating institutions in 20 countries approved the 
protocol; all patients gave written informed consent. The cor-
responding author had full access to all the trial data and takes 
responsibility for its integrity and the data analysis. The data 
that support the findings of this study are available from the 
corresponding author on reasonable request.
Study Patients
Patients were enrolled if they were in New York Heart 
Association (NYHA) functional class II to IV, had a left ventricu-
lar ejection fraction ≤40%, and an elevated N-terminal pro-B-
type natriuretic peptide level. Investigators were also asked to 
ensure individually optimized use of guideline-recommended 
pharmacological and device therapy. The main exclusions to 
enrollment were a history of type 1 diabetes, symptomatic 
hypotension/systolic blood pressure <95 mm Hg, and esti-
mated glomerular filtration rate <30 mL·min–1·1.73 m–2.
HF Hospitalizations
The primary outcome of DAPA-HF was the composite of 
worsening HF (HF hospitalization or urgent visit for HF 
requiring intravenous therapy) or cardiovascular death, 
whichever occurred first. In this analysis, we explore the 
predefined secondary end point of total (first and recur-
rent) hospitalizations for HF and cardiovascular death. 
Hospitalizations occurring on the day of death were not 
counted in this analysis.
In addition, we explored a post hoc outcome of recurrent 
worsening of HF (HF hospitalizations or urgent visit requiring 
intravenous therapy) and cardiovascular death. This compos-
ite, analyzed as time-to-first event, was the primary outcome 
of the trial, but this analysis examined total episodes of wors-
ening HF (ie, first and subsequent episodes).
Clinical Perspective
What Is New?
• In the placebo-controlled DAPA-HF trial (Dapa-
gliflozin and Prevention of Adverse-Outcomes in 
Heart Failure), dapagliflozin reduced the risk of 
total hospitalizations in patients with heart fail-
ure with reduced ejection fraction, even when the 
concomitant reduction in cardiovascular death was 
accounted for.
• Factors associated with more hospitalizations were 
male sex, higher heart rate, N-terminal pro-B-type 
natriuretic peptide, New York Heart Association 
class, type 2 diabetes, and longer duration of heart 
failure with fewer hospitalizations in those with 
higher systolic blood pressure and higher ejection 
fraction.
What Are the Clinical Implications?
• Patients who are at risk of multiple hospitaliza-
tions can be identified from easily measured 
characteristics.
• Dapagliflozin reduced the burden of heart failure 
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Baseline characteristics were summarized as means (stan-
dard deviations), median (interquartile ranges), or per-
centages. Rates were calculated using the total number 
of hospitalizations and cardiovascular deaths divided by 
the patient years of follow-up and expressed as a rate per 
100 patient-years. Recurrent events were examined by 
using 2 methods that were prespecified in the statistical 
analysis plan. The first method was by the semiparametric 
proportional-rates model described by Lin Wei Yang Ying 
(LWYY).12 This is an extension of the proportional-hazards 
model and is based on the gap-time approach that consid-
ers the times since the previous event, that is, the inter-
event time. The LWYY model uses robust standard errors 
to account for the interdependence of events within an 
individual. Subgroup estimates using the subgroups pre-
defined for the primary efficacy analysis of the trial were 
also calculated by using the LWYY method and the interac-
tion term was tested. In a post hoc analysis, an adjusted 
model was also constructed using variables previously 
known to be associated with outcomes in HFrEF and vari-
ables that differed at baseline according to the number 
of repeat hospitalizations. The second statistical method 
for the analysis of recurrent hospitalizations that was pre-
specified in the statistical analysis plan was the joint frailty 
model.9 This method allows for the within-subject associa-
tion between HF hospitalizations and subsequent mortality 
and the competing risk of mortality on HF hospitalization 
to be accounted for. The advantage of this model is that 
it allows a distinct treatment effect to be estimated for 
each of the individual outcomes while taking account of 
the association between the 2 through a common frailty 
term, where “frailty” is a random term specific to a subject 
that accounts for some patients being at higher risk (large 
frailty) than others (who have a small frailty). A rate ratio 
for the effect of dapagliflozin on HF hospitalizations and 
hazard ratio for cardiovascular death are provided sepa-
rately for the joint model. For both the LWYY and joint 
frailty models, individuals were censored at the end of fol-
low-up or at death if this was a noncardiovascular death. 
Recurrent hospitalizations were plotted using nonparamet-
ric estimates of the marginal mean of the cumulative num-
ber of recurrent HF hospitalizations over time, allowing for 
death as the terminal event according to the approach of 
Ghosh and Lin.13 The number needed to treat (NNT) was 
calculated using a negative binomial model for comparison 
with the previous literature on NNT in recurrent events in 
HF.14 However, given that dapagliflozin reduced the risk of 
cardiovascular death, and the first HF hospitalization in the 
trial, as well, we calculated the NNT from the joint frailty 
model so that we could account for the competing risk 
of death when calculating the NNT, because the negative 
binomial method censors deaths and does not account for 
the interdependence on recurrent events in the analysis.15 
In a sensitivity analysis, we examined the composite end 
point of all-cause death or total HF hospitalizations using 
the LWYY method to account for all potential causes of 
death including noncardiovascular deaths. All analyses 
were conducted using Stata version 16.1 and SAS version 
9.4. A P value <0.05 was considered statistically significant.
RESULTS
Among the 4744 participants randomly assigned in 
DAPA-HF, 548 patients experienced a total of 809 HF 
hospitalizations (Figure  1). Most patients hospitalized 
had 1 or 2 admissions during the median follow-up of 
18.2 months (Q1–Q3, 14.2–21.5). The largest number 
of hospitalizations was 7. The number of hospitaliza-
tions was higher in the placebo group (469 admissions 
among 318 patients) than in the dapagliflozin group 
(340 admissions among 230 patients; Figure 2). There 
were 500 cardiovascular deaths (227 in the dapa-
gliflozin group and 273 in the placebo group) and 105 
noncardiovascular deaths (49 in the dapagliflozin group 
and 56 in the placebo group).
Baseline Characteristics
Compared with participants who were not hospital-
ized for HF, those admitted were older, more likely to 
be men, and White. There was no significant difference 
according to geographical region. Hospitalized patients 
had worse NYHA class, higher heart rate, higher body 
mass index, higher N-terminal pro-B-type natriuretic 
peptide, lower blood pressure, lower ejection fraction, 
and lower estimated glomerular filtration rate than 
those not hospitalized. Compared with patients not 
hospitalized, those admitted at least once were more 
likely to have a history of atrial fibrillation, hyperten-
sion, type 2 diabetes, and chronic kidney disease. There 
was no difference in history of myocardial infarction or 
ischemic origin between people hospitalized and not 
hospitalized. Hospitalized patients were more likely to 
have longer-duration HF and a previous hospital admis-
sion for HF. Among those with previous HF hospital-
ization, patients who were hospitalized during the trial 
had a more recent hospital admission than participants 
who were not admitted during the trial (who had a 
more remote previous admission).
Hospitalized patients were more likely to have an im-
plantable cardioverter defibrillator and receive digoxin 
and less likely to be treated with an angiotensin-con-
verting enzyme inhibitor, angiotensin receptor blocker, 
or angiotensin receptor neprilysin inhibitor.
The differences described between patients with and 
without a hospitalization during follow-up were gen-
erally more marked among individuals with ≥2 admis-
sions, compared with 1 admission (Table).
Predictors of Repeat Events
In a multivariable model, men were more likely to 
have a recurrent hospitalization for HF or cardiovas-
cular death (Figure 3). Those in NYHA class III/IV were 
more likely to have a recurrent HF hospitalization than 
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compared with those without type 2 diabetes. Pa-
tients with a longer duration of HF were more likely 
to have a recurrent HF hospitalization than those with 
a duration of <1 year. Higher heart rate and higher N-
terminal pro-B-type natriuretic peptide also predicted 
a higher risk of recurrent HF hospitalization or cardio-
vascular death. Having had no HF hospitalization be-
fore randomization was associated with a lower risk of 
a recurrent hospitalization, as was better renal func-
tion and randomization to dapagliflozin.
Effect of Dapagliflozin on Total HF 
Hospitalizations and Cardiovascular 
Death
The rate of total (first and recurrent) HF hospitalizations 
and cardiovascular death was 21.6 per 100 patient-
years in the placebo group and 16.3 per 100 patient-
years in the dapagliflozin group. This compares with 
time-to-first event rates of 15.3 per 100 patient-years 
and 11.4 per 100 patient-years, respectively, for the 
same event composite.
The rate ratio for dapagliflozin versus placebo from 
the LWYY model was 0.75 (95% CI, 0.65–0.88), 
P=0.0002 (Figure 4), which was identical to the hazard 
ratio from time-to-first event analysis of HF hospitaliza-
tion or cardiovascular death (Figure  5) suggesting no 
attenuation of the efficacy of dapagliflozin over recur-
rent events.
In the joint frailty model, the rate ratio for total 
HF hospitalizations was 0.71 (95% CI, 0.61–0.82), 
P<0.0001, whereas, for cardiovascular death, the 
hazard ratio was 0.81 (95% CI, 0.67–0.98), P=0.028. 
The corresponding hazard ratios from the time-to-
first event analyses were 0.70 (0.59–0.83; P<0.0001) 
and 0.82 (0.69–0.98; P=0.029) for HF hospitalization 
and cardiovascular death, respectively. We calculated 
that the NNT based on the negative binomial model 
Figure 1. Number of extra cardiovascular 
(CV) deaths and heart failure (HF) hospi-
talizations in a recurrent-events analysis 
compared with time-to-first event analysis 
by treatment group.
Figure 2. Number of patients with ≥1 hospi-
talization in the dapagliflozin and placebo 
groups.
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Table. Baseline Characteristics by Number of HF Hospitalizations
Characteristics
0 HFH  
n=4196
1 HFH  
n=380




Age 66.2±10.9 67.6±10.5 67.0±11.3 0.047
Sex
 Women 994 (23.7) 83 (21.8) 32 (19.0) 0.29
 Men 3202 (76.3) 297 (78.2) 136 (81.0)  
Race/ethnicity 0.004
 White 2950 (70.3) 257 (67.6) 126 (75.0)  
 American Indian or Alaska Native 4 (0.1) 0 (0) 0 (0)  
 Asian 998 (23.8) 82 (21.6) 36 (21.4)  
 Black or African American 185 (4.4) 35 (9.2) 6 (3.6)  
 Other* 57 (1.4) 6 (1.6) 0 (0)  
Geographic region 0.23
 Asia/Pacific 981 (23.4) 80 (21.1) 35 (20.8)  
 Europe 1901 (45.3) 172 (45.3) 81 (48.2)  
 North America 581 (13.8) 70 (18.4) 26 (15.5)  
 South America 733 (17.5) 58 (15.3) 26 (15.5)  
New York Heart Association class at enrollment <0.001
 II 2909 (69.3) 206 (54.2) 88 (52.4)  
 III 1255 (29.9) 168 (44.2) 75 (44.6)  
 IV 32 (0.8) 6 (1.6) 5 (3.0)  
Baseline pulse, beats/min 71.2±11.6 73.0±12.3 74.7±12.6 <0.001
Baseline systolic blood pressure, mm Hg 122.2±16.2 119.6±17.4 118.3±15.5 <0.001
Baseline left ventricular ejection fraction, % 31.3±6.7 29.5±7.2 29.3±7.2 <0.001
Baseline N-terminal pro-B-type natriuretic peptide, pg.mL 1349 (821–2422) 2345 (1385–3968) 2693 (1465–5128) <0.001
Estimated glomerular filtration rate, mL·min–1·1.73 m–2 66.5±19.4 61.1±18.7 58.9±19.0 <0.001
Estimated glomerular filtration rate <60 mL·min–1·1.73 m–2 1641 (39.1) 198 (52.1) 87 (51.8) <0.001
Body mass index 28.1±5.9 28.7±6.6 29.2±6.4 0.018
Main cause of HF 0.53
 Ischemic 2383 (56.8) 203 (53.4) 88 (52.4)  
 Nonischemic 1474 (35.1) 147 (38.7) 66 (39.3)  
 Unknown 339 (8.1) 30 (7.9) 14 (8.3)  
Prior HF hospitalization 1935 (46.1) 211 (55.5) 105 (62.5) <0.001
History of hypertension 3090 (73.6) 304 (80.0) 128 (76.2) 0.021
History of previous myocardial infarction 1864 (44.4) 154 (40.5) 74 (44.0) 0.34
History of atrial fibrillation 1568 (37.4) 164 (43.2) 86 (51.2) <0.001
Time from diagnosis of HF <0.001
 0–3 mo 135 (3.2) 7 (1.8) 8 (4.8)  
 >3 to 6 mo 366 (8.7) 16 (4.2) 11 (6.5)  
 >6 to 12 mo 517 (12.3) 27 (7.1) 11 (6.5)  
 >1 to 2 y 621 (14.8) 48 (12.6) 17 (10.1)  
 >2 to 5 y 970 (23.1) 95 (25.0) 40 (23.8)  
 >5 y 1587 (37.8) 187 (49.2) 81 (48.2)  
Time from last HF hospitalization to randomization 0.001
 0–3 mo 307 (15.9) 31 (14.7) 30 (28.6)  
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(where cardiovascular deaths were censored) was 
23 patient-years needed to prevent 1 additional HF 
hospitalization. In the joint frailty model accounting 
for the competing risk of cardiovascular death and 
the joint frailty between recurrent HF hospitalizations 
and cardiovascular death, the NNT was 13 patient-
years needed to prevent 1 additional HF hospitaliza-
tion.
The exploratory post hoc outcome of worsening HF 
events (a HF hospitalization or urgent visit requiring in-
travenous therapy, both first and repeat) or cardiovas-
cular death added a further 39 events in 33 patients to 
the 2-component composite of total HF hospitalizations 
or cardiovascular death. The rate ratio for the effect of 
dapagliflozin on this expanded, 3-component, compos-
ite outcome was 0.74 (95% CI, 0.64–0.86), P=0.0001. 
In a sensitivity analysis of all-cause death and total HF 
hospitalizations, the results were consistent rate ratio 
0.76 (95% CI, 0.66–0.88), P=0.0002.
The efficacy of dapagliflozin did not differ by any of 
the predefined subgroups, except potentially for NYHA 
class (Figure 6). The statistical interaction was driven by 
a greater reduction in recurrent HF hospitalizations in 
those in NYHA class II, but it was not consistent with 
other markers of less advanced disease such as lower 
N-terminal pro-B-type natriuretic peptide levels.
DISCUSSION
Even during a relatively short median follow-up of 18.2 
months, most HF hospitalizations in DAPA-HF were 
repeat admissions (429 of 809 total hospitalizations, 
53%) that are ignored in conventional time-to-first 
event analysis. Both first and repeat hospitalizations 
were reduced by dapagliflozin, leading to a reduction 
in total admissions for HF.
The rationale for evaluating and preventing repeat ad-
missions is well rehearsed. In addition to their personal 
 >6 to 12 mo 442 (22.8) 62 (29.4) 19 (18.1)  
 >1 to 2 y 307 (15.9) 30 (14.2) 11 (10.5)  
 >2 to 5 y 304 (15.7) 20 (9.5) 11 (10.5)  
 >5 y 229 (11.8) 30 (14.2) 8 (7.6)  
Medical history of type 2 diabetes 1697 (40.4) 199 (52.4) 87 (51.8) <0.001
Type 2 diabetes at baseline† 1829 (43.6) 211 (55.5) 99 (58.9) <0.001
History of implantable cardioverter defibrillator or cardiac resynchronization 
therapy–defibrillator
1048 (25.0) 132 (34.7) 62 (36.9) <0.001
Cardiac resynchronization therapy–defibrillator or cardiac resynchronization 
therapy–pacemaker
300 (7.1) 38 (10.0) 16 (9.5) 0.075
Diuretics 3905 (93.1) 364 (95.8) 164 (97.6) 0.01
Angiotensin-converting enzyme inhibitor 2385 (56.8) 195 (51.3) 81 (48.2) 0.013
Angiotensin receptor blocker 1162 (27.7) 102 (26.8) 43 (25.6) 0.79
Angiotensin receptor neprilysin inhibitor 433 (10.3) 49 (12.9) 26 (15.5) 0.038
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker 3534 (84.2) 294 (77.4) 124 (73.8) <0.001
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker or 
angiotensin receptor neprilysin inhibitor
3952 (94.2) 342 (90.0) 148 (88.1) <0.001
β-Blocker 4033 (96.1) 362 (95.3) 163 (97.0) 0.58
Mineralocorticoid receptor antagonist 2985 (71.1) 256 (67.4) 129 (76.8) 0.074
Digoxin 756 (18.0) 88 (23.2) 43 (25.6) 0.003
Baseline glycohemoglobin A1c, % 7.4±1.5 7.5±1.8 7.7±1.7 0.15
Biguanide 889 (52.4) 92 (46.2) 35 (40.2) 0.029
Sulfonylurea 375 (22.1) 42 (21.1) 21 (24.1) 0.85
Dipeptidyl peptidase-4 inhibitor 274 (16.1) 274 (16.1) 7 (8.0) 0.12
Glucagon-like peptide 1 receptor agonist 15 (0.9) 3 (1.5) 3 (3.4) 0.06
Insulin 449 (26.5) 58 (29.1) 33 (37.9) 0.052
HF indicates heart failure; and HFH, heart failure hospitalization.
*Includes self-identified race that did not fit into the other categories.
†Eighty-two patients in the dapagliflozin group and 74 in the placebo group had previously undiagnosed diabetes, which was defined as a glycohemoglobin 
A1c level of ≥6.5% (≥48 mmol/mol), as measured in a central laboratory at both screening and randomization.
Table. Continued
Characteristics
0 HFH  
n=4196
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impact, each hospitalization is prognostically important. 
First, the risk of death rises sharply when a patient is ad-
mitted to the hospital for decompensated HF. Second, 
in the days after discharge, patients with HFrEF are at a 
high risk of dying. Last, each successive hospitalization 
is associated with a greater risk of death in the longer 
term. In addition to their prognostic significance, hos-
pitalizations exert a substantial burden on health care 
systems and society in general. Admissions for the treat-
ment of HF account for a large proportion of all hospital 
bed-days in many health care systems and are the main 
driver of the cost of HF around the world. It is clearly de-
sirable, therefore, to reduce repeat and first admissions, 
as well, although there is no guarantee that any given 
treatment will do this because of the development of 
tolerance (eg, with nitrates) or resistance (eg, through 
neurohumoral escape), for example, concepts not usu-
ally considered for cardiovascular therapy but familiar in 
the treatment of infection and cancer. The magnitude of 
benefit may also differ between the initial period early 
after starting therapy and during chronic treatment be-
cause of different mechanisms of action, a theoretical 
Figure 3. Variables associated with cardiovascular death or recurrent HF hospitalizations in a multivariable model using the Lin-Wei-Yang-Ying 
method to model recurrent events.
eGFR indicates estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; NTproBNP, N-terminal pro-B-type natriuretic peptide; 
NYHA, New York Heart Association; and SBP, systolic blood pressure.
Figure 4. Cumulative incidence of total 
heart failure hospitalizations and cardio-
vascular death.
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possibility relevant to sodium-glucose cotransporter 2 
inhibitors which have an initial diuretic effect. From an 
effectiveness, economic, and system perspective, treat-
ment discontinuation because of poor adherence or in-
tolerance may also result in the attenuation of treatment 
effect over time that may be underestimated in time-to-
first event analysis. Last, patients with recurrent admis-
sions may simply be refractory to the treatment tested 
and continue to be hospitalized. These points emphasize 
that not only does time-to-first event analysis underesti-
mate the morbidity/mortality burden of the disease, but 
it also may over- or underestimate the benefit of therapy.
In the case of dapagliflozin, the effect of treatment 
on hospitalizations and death was sustained over time, 
in keeping with its effects on patient-reported out-
comes and physiological measures such as glycohemo-
globin A1c and hematocrit. Consequently, in DAPA-HF, 
time-to-first event analysis underestimated the absolute 
benefit of therapy. Because the relative risk reduction 
with dapagliflozin on total events was identical to that 
on first events, the total number of hospitalizations 
prevented was larger when all events were accounted 
for. Specifically, when we accounted for the competing 
risk of cardiovascular death, the risk of which is also 
Figure 5. Effect of dapagliflozin on cardio-
vascular death or HF hospitalization using 
a time-to-first event Cox model, recurrent 
HF hospitalizations or cardiovascular death 
using the LWYY method and joint frailty 
model.
CV indicates cardiovascular; HF, heart failure; 
and LWYY, Lin-Wei-Yang-Ying.
Figure 6. Effect of dapagliflozin compared 
with placebo on recurrent heart failure 
hospitalizations or cardiovascular death 
by subgroups as modeled by the Lin-Wei-
Yang-Ying method.
AF indicates atrial fibrillation; BMI, body mass 
index; eGFR, estimated glomerular filtration 
rate; LVEF, left ventricular ejection fraction; 
MRA, mineralocorticoid receptor antagonist; 
NTproBNP, N-terminal pro-B-type natriuretic 
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reduced by dapagliflozin therapy, only 13 patient-years 
of treatment were needed to prevent 1 hospitalization. 
As reported previously, the equivalent treatment time to 
prevent a first HF hospitalization was 35 patient-years. 
We also found that accounting for competing noncar-
diovascular deaths in a composite of all-cause death or 
HF hospitalizations did not change our findings given 
that most deaths were cardiovascular in origin and that 
dapagliflozin also reduced the risk of all-cause death. 
Very few other trials have examined patient-time–based 
treatment effects on total events. In an analysis of SHIFT 
(Systolic Heart Failure Treatment with the IF Inhibitor Iv-
abradine Trial) 14 patient-years were needed to prevent 
1 additional HF hospitalization, although ivabradine 
had no effect on cardiovascular death in the trial, and 
the analysis was conducted using a negative binomial 
model that is suboptimal in the context of a therapy 
that also reduces cardiovascular death.14
The same considerations apply to the analysis of to-
tal HF hospitalizations plus cardiovascular death, where 
there were 1309 events, compared with 877 patients in 
the time-to-first event analysis, again demonstrating an 
almost 50% loss of events carrying information about 
the morbidity and mortality related to HFrEF when only 
the conventional time-to-first event analysis is used. The 
absolute risk reduction with dapagliflozin was greater 
for total HF hospitalizations plus cardiovascular death 
compared with this composite analyzed as time-to-first 
event. In general, the benefit of dapagliflozin on total 
HF hospitalizations plus cardiovascular death was also 
consistent in all prespecified subgroups.
The EMPEROR-Reduced trial (Empagliflozin Out-
come Trial in Patients With Chronic Heart Failure and 
a Reduced Ejection Fraction) recently showed that a 
different sodium-glucose cotransporter 2 inhibitor 
reduced the primary composite outcome of time-to-
first occurrence of HF hospitalization or cardiovascular 
death in patients with HFrEF, with a hazard ratio of 
0.75 (0.65–0.86), a treatment effect nearly identical to 
the effect of dapagliflozin on the same outcome (haz-
ard ratio, 0.75; 0.65–0.85) in DAPA-HF. In EMPEROR-
Reduced, a joint frailty model was used to estimate 
the effect of empagliflozin on total HF hospitaliza-
tions, giving a rate ratio of 0.70 (95% CI, 0.58–0.85; 
P<0.001); the hazard ratio for cardiovascular death 
was not reported because the reduction in cardio-
vascular deaths was not statistically significant.16 This 
compared with a rate ratio of 0.71 (95% CI, 0.61–
0.82; P<0.001) in DAPA-HF, even after accounting 
for the reduction in cardiovascular death with dapa-
gliflozin. A post hoc analysis of EMPORER-Reduced 
using the LWYY method of analyzing total HF hospi-
talizations or cardiovascular death gave a rate ratio of 
0.76 (95% CI, 0.65–0.89).17 Our findings are also con-
sistent with reports of the effects of cardiac resynchro-
nization therapy and sacubitril/valsartan, eplerenone, 
ivabradine, and hydralazine-isosorbide dinitrate,18 al-
though similar analyses have not been done for other 
evidence-based pharmacological therapy in HFrEF. In 
each of these reports, the relative risk reduction for to-
tal events and first events has been very similar, which 
appears to be different from 2 studies in HF with pre-
served ejection fraction where the competing risk of 
death from cardiovascular causes is much smaller, and 
the beneficial effect on total HF hospitalizations was 
larger than on first events.
Although we have advocated the use of recurrent 
events as an end point in clinical trials, and this has been 
accepted by both the US Food and Drug Administration 
and the European Medicines Agency,19,20 the decision 
to adopt such an approach may be a difficult choice for 
sponsors. For the reasons described above, there are 
several treatment- and patient-related reasons why the 
effect of therapy on second and subsequent events may 
be less than on first events. Drop-in use of study treat-
ment or alternative effective therapies after a first hos-
pitalization may also diminish the difference between 
the placebo and active treatment groups. Designing a 
trial with a recurrent events primary end point is also 
more difficult because factors such as heterogeneity of 
patient risk, not currently a part of routine power calcu-
lations, must be considered and sample size estimation 
is more complex.8 Nevertheless, we would still argue 
that analysis of recurrent events should at least be a 
prespecified secondary end point in view of the clini-
cal importance of establishing the effect of therapy on 
total and not just first events.
Last, although the optimal statistical method for the 
analyses we have described is still open to discussion,21 
we used 2 that have gained favor, a joint frailty model 
and the LWYY method, and found that their results 
were consistent. Moreover, the robustness and  limita-
tions of other methods in the setting of HF have been 
discussed elsewhere.9,22–24
Limitations
As with any clinical trial, the follow-up time was limited, 
and the effect of treatment on total events might be 
different over longer periods of observation. We were 
only able to study 2 types of events, and, although 
we would have also liked to investigate urgent visits 
for worsening HF requiring intravenous therapy, few of 
these events occurred in DAPA-HF.
Conclusions
In summary, in patients with HFrEF, compared with pla-
cebo, dapagliflozin reduced the risk of total (first and 
recurrent) HF hospitalizations and cardiovascular death. 
Recurrent hospitalizations remain a common problem 
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